NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock Has Consensus Price Target of $48.90 According to Analysts

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have been assigned an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $48.70.

A number of equities research analysts have issued reports on the stock. Royal Bank Of Canada reduced their price objective on shares of NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating on the stock in a research note on Monday, October 5th. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, November 1st. BMO Capital Markets started coverage on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. They set an “outperform” rating and a $58.00 target price on the stock. Jefferies Financial Group restated a “buy” rating and set a $45.00 price target on shares of NewAmsterdam Pharma in a report on Monday, July 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $52.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, September 8th.

NewAmsterdam Pharma Trading Down 9.7%

Shares of NAMS stock opened at $18.89 on Friday. The stock has a market cap of $2.26 billion, a P/E ratio of -11.18 and a beta of 0.15. NewAmsterdam Pharma has a 1 year low of $18.86 and a 1 year high of $42.21. The stock has a 50 day simple moving average of $22.26 and a 200 day simple moving average of $29.59.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.33. The firm had revenue of $19.16 million for the quarter, compared to analyst estimates of $8.82 million. NewAmsterdam Pharma had a negative return on equity of 31.04% and a negative net margin of 789.95%. Analysts forecast that NewAmsterdam Pharma will post -1.82 EPS for the current year.

Key Headlines Impacting NewAmsterdam Pharma

Here are the key news stories impacting NewAmsterdam Pharma this week:

• Positive Sentiment: The European Commission approved Ubeslo® (obicetrapib) and Evlarco® (obicetrapib plus ezetimibe), the first worldwide regulatory approvals for obicetrapib. The approvals are an important step toward potential commercialization. Company update and results
• Positive Sentiment: Third-quarter results beat estimates: the company reported a loss of $0.14 per share versus the expected $0.47 loss, while revenue of $19.16 million exceeded the $8.82 million consensus. Q3 results
• Positive Sentiment: Stifel described the investment setup as compelling and significantly tilted toward upside, supporting the bullish analyst view. Stifel analyst comments
• Neutral Sentiment: Needham lowered its price target from $48 to $46 but maintained a Buy rating. The cut is modest relative to the target, which still implies substantial upside from the reference price in the report.

Insider Transactions at NewAmsterdam Pharma

In related news, CEO Michael H. Davidson acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The stock was acquired at an average cost of $22.65 per share, for a total transaction of $226,500.00. Following the completion of the acquisition, the chief executive officer directly owned 792,923 shares of the company’s stock, valued at approximately $17,959,705.95. This trade represents a 1.28% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director John W. Smither sold 1,600 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $25.32, for a total value of $40,512.00. Following the transaction, the director directly owned 8,760 shares of the company’s stock, valued at approximately $221,803.20. This represents a 15.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 176,846 shares of company stock worth $4,661,919. Company insiders own 12.74% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

Institutional investors have recently made changes to their positions in the stock. KBC Group NV acquired a new stake in NewAmsterdam Pharma in the first quarter valued at approximately $37,000. Parallel Advisors LLC grew its position in NewAmsterdam Pharma by 43.7% in the 3rd quarter. Parallel Advisors LLC now owns 2,012 shares of the company’s stock valued at $49,000 after purchasing an additional 612 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in NewAmsterdam Pharma during the 3rd quarter valued at $149,000. CenterBook Partners LP bought a new position in shares of NewAmsterdam Pharma in the third quarter valued at $290,000. Finally, PNC Financial Services Group Inc. grew its holdings in shares of NewAmsterdam Pharma by 147.7% during the first quarter. PNC Financial Services Group Inc. now owns 9,119 shares of the company’s stock valued at $292,000 after buying an additional 5,437 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma (NASDAQ: NAMS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases. The company’s primary investigational product is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and potentially address residual cardiovascular risk in patients who remain inadequately controlled on existing treatments.

NewAmsterdam is evaluating obicetrapib in late-stage clinical studies involving patients with dyslipidemia, including individuals with heterozygous familial hypercholesterolemia and patients who are unable to reach cholesterol goals with currently available therapies.